Cocrystal Pharma Reports CC-42344 Shows 1,000-fold Greater Potency Than Tamiflu Against H5N1 Avian Flu

Cocrystal Pharma, Inc.

CC-42344 exhibited EC50 of 0.003 µM against the 2024 Texas H5N1 strain, ~1,000-fold more potent than Tamiflu (EC50 2.69 µM).
The PB2 inhibitor targets a highly conserved active site and has shown favorable safety in a Phase 1 study.
H5N1 has spread in U.S. dairy cattle since March 2024, with rare human cases and low population immunity according to CDC.
Cocrystal plans further clinical evaluation of CC-42344 for pandemic and seasonal influenza treatment.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.